Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Not Confirmed
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Not Confirmed
Not Confirmed
05-08 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Industry Trade Show
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Industry Trade Show
Not Confirmed
05-08 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
02 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spinogenix-announces-positive-type-c-meeting-with-the-fda-for-spg601-in-patients-with-fragile-x-syndrome-fxs-302543653.html
08 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spinogenix-announces-positive-first-cohort-results-from-phase-2a-trial-evaluating-spg302-for-alzheimers-disease-302524227.html
07 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/european-medicines-agency-grants-orphan-drug-designation-to-spinogenixs-spg601-for-treatment-of-fragile-x-syndrome-fxs-302498713.html
24 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spinogenix-announces-full-enrollment-in-its-phase-2-trial-evaluating-spg302-as-a-first-in-class-synaptic-regenerative-therapy-for-alzheimers-disease-302489503.html
03 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spinogenixs-spg302-the-first-synaptic-regenerative-therapy-to-treat-als-granted-orphan-drug-designation-by-the-european-medicines-agency-302471747.html
05 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spinogenix-announces-fda-authorized-expanded-access-program-for-spg302-the-first-synaptic-regenerative-therapy-to-treat-als-302445835.html
ABOUT THIS PAGE